标题
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
作者
关键词
-
出版物
LABORATORY INVESTIGATION
Volume 97, Issue 9, Pages 1063-1071
出版商
Springer Nature
发表日期
2017-07-24
DOI
10.1038/labinvest.2017.64
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant
- (2017) Noah Frydenlund et al. MODERN PATHOLOGY
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- The efficacy of anti-PD-1 agents in acral and mucosal melanoma
- (2016) Alexander N. Shoushtari et al. CANCER
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
- (2016) Sehui Kim et al. HUMAN PATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry
- (2016) Jinhyun Cho et al. INVESTIGATIONAL NEW DRUGS
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- (2016) Lisa A. Kottschade et al. MELANOMA RESEARCH
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
- (2016) Ludmila Danilova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
- (2016) Chan-Young Ock et al. Oncotarget
- Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
- (2016) Catherine Sautès-Fridman et al. Frontiers in Immunology
- Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
- (2016) Ioannis Karydis et al. OncoImmunology
- PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
- (2016) Joseph M. Obeid et al. OncoImmunology
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases
- (2015) Hao Song et al. HISTOPATHOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin
- (2015) Marie L. Bønnelykke-Behrndtz et al. MELANOMA RESEARCH
- Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck
- (2015) Julia Thierauf et al. MELANOMA RESEARCH
- Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis
- (2015) Stephan W Jahn et al. MODERN PATHOLOGY
- Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
- (2015) A Hunter Shain et al. NATURE GENETICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis
- (2014) Simon J. Furney et al. Pigment Cell & Melanoma Research
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
- (2014) N. Rodi et al. Cancer Immunology Research
- The Clinical Significance of Tumor-Infiltrating Lymphocytes and Microscopic Satellites in Acral Melanoma in a Korean Population
- (2013) Seok-Jong Lee et al. Annals of Dermatology
- Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
- (2013) Simon J Furney et al. JOURNAL OF PATHOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?
- (2012) Jerry Y. Niederkorn Frontiers in Immunology
- The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
- (2011) David C. Whiteman et al. Pigment Cell & Melanoma Research
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now